Jaguar Health (HAM:1JA) 3-Year EBITDA Growth Rate : 79.20% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Jaguar Health 3-Year EBITDA Growth Rate?

Jaguar Health's EBITDA per Share for the three months ended in Mar. 2024 was €-2.83.

During the past 3 years, the average EBITDA Per Share Growth Rate was 79.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Jaguar Health was 79.20% per year. The lowest was 63.40% per year. And the median was 71.30% per year.

Competitive Comparison of Jaguar Health's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Jaguar Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jaguar Health's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Jaguar Health's 3-Year EBITDA Growth Rate falls into.

Jaguar Health 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Jaguar Health (HAM:1JA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Jaguar Health 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Jaguar Health's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Jaguar Health (HAM:1JA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (HAM:1JA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

JAGX:USA 1JAA:Germany

Address

200 Pine Street, Suite 400, San Francisco, CA, USA, 94104

Website

http://www.jaguar.health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Jaguar Health (HAM:1JA) Headlines

No Headlines